A charity says it is "disappointed" over a decision not to provide a life-extending breast cancer drug on the NHS. The National Institute for Health and Care Excellence concluded it could not be predicted how long pertuzumab extended people's lives.
The National Institute for Health and Care Excellence (Nice) says it cannot recommend breast cancer drug pertuzumab for widespread use because clinical trial data could not predict how long the drug might extend people's lives for.
The organisation has now launched a consultation to hear the views of charities, patient groups and drug manufacturers.
Nice chief executive Sir Andrew Dillon said: "The appraisal committee couldn't be sure of the benefits of pertuzumab.
"The main clinical trial did not reflect current medical practice in the UK and despite the research data suggesting the treatment could help delay the growth and spread of the disease, the evidence was not robust enough to confirm for how long pertuzumab may actually extend people's lives."
The Democratic presidential candidate may also have shown his cards on his choice of running mate.
The US president also shared a post on Twitter accusing Dr Anthony Fauci of misleading the public over hydroxychloroquine.
Fears over an impending second wave of coronavirus dominates Wednesday’s front pages.